INR 105.3
(1.4%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 156.14 Million INR | -45.92% |
2022 | 235.52 Million INR | -5.36% |
2021 | 248.84 Million INR | 13.41% |
2020 | 219.41 Million INR | -12.52% |
2019 | 250.8 Million INR | 5.43% |
2018 | 237.87 Million INR | 19.17% |
2017 | 199.6 Million INR | 15.63% |
2016 | 172.63 Million INR | 18.63% |
2015 | 145.51 Million INR | -24.27% |
2014 | 192.13 Million INR | -18.05% |
2013 | 234.45 Million INR | 34.92% |
2012 | 173.77 Million INR | 64.17% |
2011 | 105.84 Million INR | 15.62% |
2010 | 91.54 Million INR | 30.48% |
2009 | 70.16 Million INR | -10.9% |
2008 | 78.74 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 25.64 Million INR | 69.8% |
2023 Q4 | 37.79 Million INR | -49.13% |
2023 Q1 | 51.18 Million INR | -28.9% |
2023 Q2 | 72.14 Million INR | 40.96% |
2023 Q3 | 74.28 Million INR | 2.96% |
2023 FY | 127.38 Million INR | -45.92% |
2022 Q2 | 50.84 Million INR | 6.53% |
2022 FY | 235.52 Million INR | -5.36% |
2022 Q4 | 71.99 Million INR | 11.57% |
2022 Q3 | 64.52 Million INR | 26.92% |
2022 Q1 | 47.72 Million INR | -24.75% |
2021 Q3 | 65.55 Million INR | 18.78% |
2021 Q4 | 63.41 Million INR | -3.27% |
2021 Q2 | 55.19 Million INR | -14.66% |
2021 Q1 | 64.67 Million INR | 271.56% |
2021 FY | 248.84 Million INR | 13.41% |
2020 Q2 | 66.03 Million INR | 28.79% |
2020 Q4 | 17.4 Million INR | -81.37% |
2020 Q1 | 51.27 Million INR | 0.08% |
2020 FY | 219.41 Million INR | -12.52% |
2020 Q3 | 93.42 Million INR | 41.48% |
2019 Q3 | 72.69 Million INR | 10.09% |
2019 FY | 250.8 Million INR | 5.43% |
2019 Q1 | 60.84 Million INR | 15.7% |
2019 Q2 | 66.03 Million INR | 8.52% |
2019 Q4 | 51.23 Million INR | -29.53% |
2018 Q3 | 67.74 Million INR | 7.08% |
2018 Q1 | 47.42 Million INR | 0.0% |
2018 FY | 237.87 Million INR | 19.17% |
2018 Q4 | 52.58 Million INR | -22.38% |
2018 Q2 | 63.26 Million INR | 33.41% |
2017 FY | 199.6 Million INR | 15.63% |
2016 FY | 172.63 Million INR | 18.63% |
2015 FY | 145.51 Million INR | -24.27% |
2015 Q2 | 27.88 Million INR | -7.37% |
2015 Q1 | 30.1 Million INR | -24.87% |
2014 Q1 | 65.31 Million INR | 71.29% |
2014 Q2 | 66.01 Million INR | 1.08% |
2014 Q3 | 28.81 Million INR | -56.35% |
2014 Q4 | 40.07 Million INR | 39.06% |
2014 FY | 192.13 Million INR | -18.05% |
2013 FY | 234.45 Million INR | 34.92% |
2013 Q2 | 66.34 Million INR | 10.0% |
2013 Q3 | 69.65 Million INR | 4.98% |
2013 Q4 | 38.13 Million INR | -45.26% |
2013 Q1 | 60.31 Million INR | 41.71% |
2012 Q3 | 60.36 Million INR | 59.44% |
2012 Q2 | 37.85 Million INR | 10.7% |
2012 Q1 | 34.19 Million INR | 193.81% |
2012 FY | 173.77 Million INR | 64.17% |
2012 Q4 | 42.56 Million INR | -29.49% |
2011 Q3 | 31.2 Million INR | 0.0% |
2011 Q4 | 11.63 Million INR | -62.69% |
2011 FY | 105.84 Million INR | 15.62% |
2010 FY | 91.54 Million INR | 30.48% |
2009 FY | 70.16 Million INR | -10.9% |
2008 FY | 78.74 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 99.016% |
Aurobindo Pharma Limited | 39.23 Billion INR | 99.602% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 98.659% |
Granules India Limited | 7.18 Billion INR | 97.826% |
Indoco Remedies Limited | 4.74 Billion INR | 96.712% |
Achyut Healthcare Limited | 1.6 Million INR | -9604.599% |
Ajanta Pharma Limited | 30.46 Billion INR | 99.487% |
Alkem Laboratories Limited | 32.83 Billion INR | 99.524% |
Brooks Laboratories Limited | 51.18 Million INR | -205.094% |
AstraZeneca Pharma India Limited | 2.6 Billion INR | 93.995% |
Bajaj HealthCare Limited | 985.34 Million INR | 84.153% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 88.998% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.837% |
Eris Lifesciences Limited | 4.94 Billion INR | 96.841% |
FDC Limited | 5.34 Billion INR | 97.081% |
Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 99.769% |
Gufic Biosciences Limited | 1.07 Billion INR | 85.511% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 92.649% |
Ipca Laboratories Limited | 13.91 Billion INR | 98.878% |
Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | 79.811% |
Krebs Biochemicals & Industries Limited | 46.15 Million INR | -238.303% |
Lasa Supergenerics Limited | 291.17 Million INR | 46.373% |
Laurus Labs Limited | 3.01 Billion INR | 94.814% |
Lupin Limited | 95.67 Billion INR | 99.837% |
Mankind Pharma Limited | 23.15 Billion INR | 99.326% |
Medicamen Biotech Limited | 335.16 Million INR | 53.412% |
Medico Remedies Limited | 161.84 Million INR | 3.52% |
Megasoft Limited | 49.52 Million INR | -215.27% |
NATCO Pharma Limited | 10.05 Billion INR | 98.448% |
Piramal Pharma Limited | 19.91 Billion INR | 99.216% |
RPG Life Sciences Limited | 1.63 Billion INR | 90.453% |
Sigachi Industries Limited | 579.88 Million INR | 73.073% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.899% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 88.869% |
Syncom Formulations (India) Limited | 942.39 Million INR | 83.431% |
Unichem Laboratories Limited | 6.72 Billion INR | 97.678% |
Wanbury Limited | 1.16 Billion INR | 86.55% |
Windlas Biotech Limited | 1 Billion INR | 84.486% |
ZIM Laboratories Limited | 1.01 Billion INR | 84.587% |
Zydus Lifesciences Limited | 43.17 Billion INR | 99.638% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 94.925% |
Divi's Laboratories Limited | 14.17 Billion INR | 98.898% |
Hester Biosciences Limited | 908.84 Million INR | 82.819% |
Procter & Gamble Health Limited | 2.99 Billion INR | 94.787% |
Amrutanjan Health Care Limited | 1.09 Billion INR | 85.792% |
Bal Pharma Limited | 389.89 Million INR | 59.951% |
Strides Pharma Science Limited | 9.16 Billion INR | 98.296% |
Venus Remedies Limited | 1.91 Billion INR | 91.852% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 94.921% |
Nectar Lifesciences Limited | 625.55 Million INR | 75.038% |
Shilpa Medicare Limited | 2.18 Billion INR | 92.839% |
Aarti Drugs Limited | 1.16 Billion INR | 86.625% |
IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | 85.789% |
Suven Life Sciences Limited | 109.75 Million INR | -42.275% |
Ind-Swift Limited | 946.56 Million INR | 83.504% |
Valiant Laboratories Limited | 36.28 Million INR | -330.287% |
J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 98.145% |
Solara Active Pharma Sciences Limited | 4.57 Billion INR | 96.59% |
Themis Medicare Limited | 782.85 Million INR | 80.054% |
Hikal Limited | 2.48 Billion INR | 93.72% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 99.271% |
Sequent Scientific Limited | 2.9 Billion INR | 94.619% |
Novartis India Limited | 470.1 Million INR | 66.784% |
Wockhardt Limited | 6.4 Billion INR | 97.56% |
Jubilant Pharmova Limited | 14.45 Billion INR | 98.92% |
Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -863.294% |
Neuland Laboratories Limited | 2.92 Billion INR | 94.67% |
Morepen Laboratories Limited | 1.98 Billion INR | 92.143% |
Kilitch Drugs (India) Limited | 412.42 Million INR | 62.139% |
Mangalam Drugs & Organics Limited | 676.14 Million INR | 76.906% |